Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with knee osteoarthritis (wear-and-tear arthritis) who are scheduled to get platelet-rich plasma (PRP) injections in the knee. It studies whether simple blood count ratios can predict who responds.

Életkor

40 to 60 years

Nem

All sexes

A betegség stádiuma

Primary knee osteoarthritis with symptoms, Kellgren-Lawrence grade 2 or 3 on X-rays taken while standing. Body mass index below 40.

Korábbi kezelés

People must be planned to receive a course of PRP injections in the studied knee. No injection into that knee within the previous 6 months.

A részvétel fő kizáró okai

• Body-wide inflammatory or autoimmune disease
• Active acute infection when joining
• Current blood thinners or anti-platelet drugs, or current or recent chemotherapy
• Any medical reason PRP cannot be used, per the 2025 GRIIP guidance
• Unable to attend the planned follow-up visits

A regiszter feltételei, szó szerint

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

• 40 és 60 év között vagy?IgenNem

Mit akar kideríteni a vizsgálat

Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.